IP Library Patent Application 17692090
Patent Application
App. No. 17/692,090

METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/692,090
Abstract

This disclosure relates to methods administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.

Claims (19)

1 . A dosage form comprising about 5 mg to about 30 mg of a tetrabenazine and about 50 mg to about 200 mg of a bupropion as the only active pharmaceutical agents in the dosage form.

2 . The dosage form of claim 1 , comprising about 5 mg to about 20 mg of the tetrabenazine.

3 . The dosage form of claim 2 , comprising about 70 mg to about 140 mg of the bupropion.

4 . The dosage form of claim 1 , comprising about 70 mg to about 140 mg of the bupropion.

5 . The dosage form of claim 1 , comprising about 10 mg to about 15 mg of the tetrabenazine.

6 . The dosage form of claim 5 , comprising about 90 mg to about 110 mg of the bupropion.

7 . The dosage form of claim 1 , comprising about 90 mg to about 110 mg of the bupropion.

8 . The dosage form of claim 7 , which provides sustained release of the bupropion.

9 . The dosage form of claim 7 , having a weight ratio of tetrabenazine to bupropion that is about 0.1 to about 0.3.

10 . The dosage form of claim 1 , which provides sustained release of the bupropion.

11 . The dosage form of claim 1 , having a weight ratio of tetrabenazine to bupropion that is about 0.1 to about 0.3.

12 . The dosage form of claim 1 , wherein the tetrabenazine is not deuterium-modified.

13 . The dosage form of claim 1 , wherein the bupropion is not deuterium-modified.

14 . The dosage form of claim 1 , wherein the bupropion has an enantiomeric excess of S-bupropion.

15 . The dosage form of claim 1 , wherein the bupropion has an enantiomeric excess of at least 97% of S-bupropion.

16 . The dosage form of claim 1 , comprising about 70 mg to about 100 mg of the bupropion.

17 . The dosage form of claim 1 , comprising about 100 mg to about 140 mg of the bupropion.

18 . The dosage form of claim 1 , comprising about 9 mg to about 12 mg of the tetrabenazine.

19 . The dosage form of claim 1 , comprising about 12 mg to about 15 mg of the tetrabenazine.

Assignments (3)
SECURITY INTEREST Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2022
From: TABUTEAU, HERRIOT
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 059231/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2022
From: TABUTEAU, HERRIOT
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 059231/0200 →